Categories
Change Password!
Reset Password!
Short-term use of nimesulide is associated with mild changes in specific liver enzymes and serum albumin, while renal function and gastrointestinal tolerability remain unaffected over a two-week period.
A clinical study evaluating the safety of nimesulide in patients with rheumatological complaints reports modest alterations in liver function parameters after two weeks of therapy, with no evidence of renal impairment or gastrointestinal (GI) adverse effects. In this prospective analysis, 50 patients (mean age 39 years; 66% male) attending a tertiary care orthopaedic outpatient clinic received nimesulide at a dose of 100 mg twice daily for 14 days. Researchers documented sociodemographic characteristics, comorbidities, and lifestyle factors such as alcohol and tobacco use. Patients were monitored weekly for clinical symptoms and laboratory changes, including blood parameters, liver function tests, and renal function markers.
The findings indicate that treatment was associated with changes in serum albumin and serum glutamic-pyruvic transaminase levels, suggesting a mild hepatic impact. However, blood urea nitrogen, serum creatinine, and routine hematological parameters remained stable, and no GI side effects were observed throughout the study period (Table 1).
Overall, the data suggest that short-term nimesulide therapy may cause limited biochemical changes in liver function without clinically significant renal or GI toxicity, though monitoring of hepatic parameters remains advisable.
International Journal of Research in Medical Sciences
A clinical study on nimesulide hepatotoxicity
Manju K. Nair et al.
Comments (0)